US · Healthcare · Drug Manufacturers - General
EPS came in at 1.47 against a street estimate of 1.40 — a beat of 5.0%.
Analysts rate GSK plc a buy (4 buy, 4 hold, 1 sell out of 9) with an average price target of $59.12.
CONFIDENT GSK delivered solid Q3 growth, specialty medicines led momentum, launches accelerated, and 2026 guidance was reaffirmed with revenue and profit toward the upper half. Q3 FY26 U.S. launches gained momentum; China faced Shingrix destocking; Japan delivered positive Hibsago reimbursement progress; international Nucala grew 21%. Analysts focused on HIV formulation timing, launch acceleration, Shingrix regional trends and 2027 pressures. Management emphasized ongoing regulatory analysis, improving launch mechanics and reaffirmed guidance. specialty growth accelerates, guidance reaffirmed Management reaffirmed 2026 guidance, with sales expected in the upper half of the range 2026-10-28…
Full summary in the app.
| Fund | Stake |
|---|---|
| FMR Inc | 3.24% |
| Dodge & Cox | 2.41% |
| Fisher Asset Management, LLC | 1.78% |
| PRIMECAP Management Company | 1.26% |
| Wellington Management Company LLP | 0.57% |
| JTC Employer Solutions Trustee Ltd | 0.43% |
| Morgan Stanley - Brokerage Accounts | 0.38% |
| Royal Bank of Canada | 0.38% |
| Document | Date |
|---|---|
| Quarterly results (6-K) · Q3 2026 HEADLINE NUMBERS • Q3 2026 turnover was £8,887 million, up 4% at AER and 5% at CER. Year-to-date turnover was £24,925 million, up 4% at AER and 5% at | 2026-10-28 |
| Ris-rez positive ph 3 osteosarcoma data in china (6-K) · Q4 2026 HEADLINE NUMBERS • GSK reported positive results from the ARTEMIS-011 Phase III trial of investigational antibody-drug conjugate risvutatug rezetecan | 2026-10-26 |
| Jemperli data show 76% complete response rate (6-K) · Q4 2026 HEADLINE NUMBERS • GSK reported interim Phase II AZUR-1 results for Jemperli (dostarlimab) as a standalone treatment in adults with stage II and III | 2026-10-26 |
| Positive mo-rez phase ib data in ovarian cancer (6-K) · Q4 2026 HEADLINE NUMBERS • GSK reported positive updated phase Ib data for investigational mocertatug rezetecan (Mo-Rez) in platinum-resistant ovarian cancer | 2026-10-26 |
| Us fda approves hibsago for chronic hepatitis b (6-K) · Q4 2026 HEADLINE NUMBERS • The US FDA approved GSK’s Hibsago (bepirovirsen) for certain adults with chronic hepatitis B (CHB), in combination with nucleos(t) | 2026-10-21 |
| Jemperli approved in msi-h/dmmr rectal cancer (6-K) · Q4 2026 HEADLINE NUMBERS • GSK received US FDA accelerated approval for Jemperli (dostarlimab) in adults with stage II and III MSI-H/dMMR locally advanced re | 2026-10-19 |
| Ris-rez positive early data in lung cancer (6-K) · Q4 2026 HEADLINE NUMBERS • GSK reported first global data for investigational risvutatug rezetecan (Ris-Rez), a B7-H3-targeted antibody-drug conjugate, in re | 2026-10-19 |
| Wendy becker cbe - new directorship (6-K) · Q4 2026 OTHER NOTABLE POINTS • GSK reported that Wendy Becker CBE, an independent Non-Executive Director, has been appointed as a Non-Executive Director of T | 2026-10-08 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | $0.44 / share ex-date Nov 13, 2026 · pay Jan 7, 2027 | 2026-11-13 |
| Dividend | $0.45 / share ex-date Aug 14, 2026 · pay Oct 8, 2026 | 2026-08-14 |
| Dividend | $0.46 / share ex-date May 15, 2026 · pay Jul 9, 2026 | 2026-05-15 |
| Dividend | $0.49 / share ex-date Feb 20, 2026 · pay Apr 9, 2026 | 2026-02-20 |
| Dividend | $0.42 / share ex-date Nov 14, 2025 · pay Jan 8, 2026 | 2025-11-14 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for GSK plc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.